| References: |
B. E. Maryanoff, D. F. McComsey, J. F. Gardocki, R. P. Shank, M. J. Costanzo, S. O. Nortey, C. R. Schneider and P. E. Setler, Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships, J. Med. Chem., 30, 1433-1454 (1987); D. F. Smith, P. N. Jensen, S. H. Poulsen, E. O. Mikkelsen, E. Elbaz and R. Glaser, Effects of pyrroloisoquinoline enantiomers ((+)-and (-)-McN-5652-Z) on behavioral and pharmacological serotonergic mechanisms in rats, Eur. J. Pharmacol., 196, 85-92 (1991); Z. Szabo, P. F. Kao, U. Scheffel, M. Suehiro, W. B. Matthews, H. T. Ravert, J. L. Musachio, S. Marenco, S. E. Kim, G. A. Ricaurte, D. F. Wong, H. N. Wagner, Jr. and R. F. Dannals, Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)-McN5652, Synapse, 20, 37-43 (1995). |
